Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionInhaled treprostinil: a therapeutic reviewSelective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseasePulmonary Hypertension and Indicators of Right Ventricular FunctionThe limits of oral therapy in pulmonary arterial hypertension managementThe molecular genetics and cellular mechanisms underlying pulmonary arterial hypertensionDrug treatment of pulmonary hypertension in childrenPharmacotherapy for pulmonary hypertensionOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseAdaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.Pulmonary arterial hypertension: a comparison between children and adultsHemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertensionQuality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertensionBloodstream infections in patients given treatment with intravenous prostanoids.Recent trends in pulmonary arterial hypertensionAssessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry.Pulmonary hypertension: diagnosis and managementPediatric pulmonary arterial hypertension.Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs [corrected]Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension.Evidence of apoptosis in right ventricular dysfunction in rheumatic mitral valve stenosis.Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the artSERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trialsPulmonary arterial hypertension: use of delayed contrast-enhanced cardiovascular magnetic resonance in risk assessment.The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension.Identifying "super responders" in pulmonary arterial hypertension.Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH).Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival.Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesTherapy for pulmonary arterial hypertension associated with systemic sclerosis.Dynamic contrast-enhanced magnetic resonance imaging in patients with pulmonary arterial hypertension.Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular functionFrom short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertensionShort-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics
P2860
Q24200714-AAEB28E4-1E90-4A92-A176-E72057616FE6Q24240009-7E954F29-99AA-45B7-9275-870550704667Q24601864-9FFA1D76-E423-4074-84C8-01BA09A15C78Q24681558-2E994323-4B5C-4D65-BC11-6AC38F5816F4Q26744781-2F88D0C7-8C58-410A-9053-33D1928D7A34Q26773209-0BB749C9-8886-47FC-92EC-F428443EC0C2Q26992278-267FE438-7175-471C-B8DF-16FCFB2E5FE3Q26996078-BB87762B-01AA-4924-86DD-379C8C2E56CBQ27022763-F7D1AB9F-8700-4FE6-8592-F876590D87A9Q27023074-E1B657D2-4F21-4772-BAB2-64948BE04C28Q27342609-C037DD64-6007-44D7-8EE9-7BA32D9C27C9Q27687320-0A851BF8-65A9-4774-831B-D519A5BFC940Q28083099-88FCAFA6-01BC-4562-844D-CDE55B7E41F1Q28544778-A5409035-6407-4B63-89CA-6961A15833DCQ30228937-373BE0CE-2B91-4735-9682-C8358EBE12A7Q30475192-59F67D72-FB10-4FBB-ABC9-B4FAAFBD11FAQ30868378-4A67A5A2-4450-4339-AE77-818C556826DDQ33157071-27CBC91A-A609-4A13-AEA0-FC7E42B07A50Q33163446-58261A09-C5CC-4E86-9084-5D9D9D94A5C0Q33405650-EDD0D21E-FFF3-43CA-8D32-AFD6E24CACA1Q33532813-3730C29B-5C1F-4B82-8031-E6B6334A7D17Q33538017-98AE2816-98D7-443D-AA63-5F096E52B2F9Q33562258-EA4685C5-DE9F-497F-88CE-CA14312E4169Q33568896-E20ACE3D-F7ED-4B0F-B10B-AE12E9CEAC65Q33587892-B9F85F04-F209-4600-A798-39BBEAC9FE3FQ33589653-82BB7F06-0D1A-4A47-9ECF-292A56815924Q33645081-26DB1B32-1B6C-4623-865F-80047CDCE863Q33670265-F92B323A-D224-4F78-A132-392BE82AC972Q33773350-A7BC2B15-D3EC-4D30-A8CC-8303612B0FA9Q33788447-98C3B4C9-8809-42A5-96AF-766F57BF9509Q33788452-1F35B805-0FFE-47CE-BAF2-D0C0503EE138Q33788506-E39BB7E8-499E-484C-9D54-6C10EEE9EBAEQ33788527-8A5EE762-396E-4FD8-8E8F-3138CD503057Q33788582-3DE529CE-F729-4C68-A5F5-49EB6DCFDF66Q33805746-03B76CD6-3F0F-486A-BB2F-1F6A1F9BD315Q33805937-9AAAC40A-EF86-4300-8B78-ADE0979380C1Q33806077-FB22BCB0-D5D7-4CE2-93CB-699E49B26D70Q33806102-8077F40E-4C77-430D-8E7D-2BDF810238F5Q33806163-BF67C91D-20FF-4EE3-B29A-2056EF944F6CQ33806168-859B199F-13FE-487E-9EC4-30B050920937
P2860
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Long-term intravenous epoprost ...... ognostic factors and survival.
@en
Long-term intravenous epoprost ...... ognostic factors and survival.
@nl
type
label
Long-term intravenous epoprost ...... ognostic factors and survival.
@en
Long-term intravenous epoprost ...... ognostic factors and survival.
@nl
prefLabel
Long-term intravenous epoprost ...... ognostic factors and survival.
@en
Long-term intravenous epoprost ...... ognostic factors and survival.
@nl
P2093
P1476
Long-term intravenous epoprost ...... rognostic factors and survival
@en
P2093
Florence Parent
Gilles Garcia
Gérald Simonneau
Hilario Nunes
Maurizio Rainisio
Philippe Hervé
P304
P356
10.1016/S0735-1097(02)02012-0
P407
P577
2002-08-01T00:00:00Z